Compare FGBI & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGBI | RCEL |
|---|---|---|
| Founded | 1934 | N/A |
| Country | United States | United States |
| Employees | 339 | 226 |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.1M | 132.0M |
| IPO Year | N/A | N/A |
| Metric | FGBI | RCEL |
|---|---|---|
| Price | $8.32 | $3.96 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.88 |
| AVG Volume (30 Days) | 5.6K | ★ 208.1K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $567.70 | $21.69 |
| Revenue Next Year | N/A | $49.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.31 | $3.22 |
| 52 Week High | $10.55 | $10.28 |
| Indicator | FGBI | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.53 | 38.27 |
| Support Level | $7.79 | $3.33 |
| Resistance Level | $8.33 | $4.09 |
| Average True Range (ATR) | 0.28 | 0.29 |
| MACD | -0.06 | -0.13 |
| Stochastic Oscillator | 22.49 | 8.59 |
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.